International Journal of Hematology

, Volume 82, Issue 5, pp 412–416 | Cite as

Myelodysplastic Syndrome

  • Shinji Nakao
  • H. Joachim Deeg
  • Takayuki Ishikawa
  • Judith Marsh
  • Alan List
  • Masao Tomonaga
Meeting Report

Key words

Myelodysplastic syndrome Bone marrow failure syndrome Immunosuppressive therapy Cyclosporine PNH-type blood cell 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199.CrossRefPubMedGoogle Scholar
  2. 2.
    Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998;100:304–309.CrossRefGoogle Scholar
  3. 3.
    Miescher PA, Favre H, Beris P. Autoimmune myelodysplasias. Semin Hematol. 1991;28:322–330.PubMedGoogle Scholar
  4. 4.
    Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997;99:699–705.CrossRefPubMedGoogle Scholar
  5. 5.
    Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002;100:3897–3902.CrossRefGoogle Scholar
  6. 6.
    Tumors WHO Co. Tumor of haematopoietic and lymphoid tissues. In: Jaffe WS ed. Pathology and Genetics. Lyon: IARS Press; 2001.Google Scholar
  7. 7.
    Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.Google Scholar
  8. 8.
    Saif MW, Hopkins JL, Gore SD. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomono- cytic leukemia. Leuk Lymphoma. 2002;43:2083–2092.CrossRefPubMedGoogle Scholar
  9. 9.
    Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002;100:1570–1574.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol. 2000;37:15–29.CrossRefPubMedGoogle Scholar
  11. 11.
    Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood. 2002;100:3639–3645.CrossRefPubMedGoogle Scholar
  12. 12.
    Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol. 1998;102:1314–1322.CrossRefPubMedGoogle Scholar
  13. 13.
    Molnar L, Berki T, Hussain A, Nemeth P, Losonczy H. Detection of TNFalpha expression in the bone marrow and determination of TNFalpha production of peripheral blood mononuclear cells in myelodysplastic syndrome. Pathol Oncol Res. 2000;6:18–23.CrossRefPubMedGoogle Scholar
  14. 14.
    Selleri C, Maciejewski JP, Catalano L, et al. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies. Cancer. 2002;95:1911–1922.CrossRefPubMedGoogle Scholar
  15. 15.
    Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med. 1999;131:401–408.CrossRefPubMedGoogle Scholar
  16. 16.
    Ishiyama K, Chuhjo T,Wang H, Yachie A, Omine M, Nakao S. Poly- clonal hematopoiesis maintained in patients with bone marrow failure harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood. 2003;102:1211–1216.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Feng X, Chuhjo T, Sugimori C, et al. Diazepam-binding inhibitor- related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood. 2004;104:2425–2431.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ruter B, Wijermans PW, Lubbert M. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol. 2004;80:128–135.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003;102:3025–3027.CrossRefGoogle Scholar
  20. 20.
    Stasi R, Amadori S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol. 2002;116:334–337.CrossRefPubMedGoogle Scholar
  21. 21.
    Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia. 2002;16:1–6.CrossRefPubMedGoogle Scholar
  22. 22.
    List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549–557.CrossRefPubMedGoogle Scholar
  23. 23.
    Aguayo A. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes. Curr Hematol Rep. 2004;3:184–191.PubMedGoogle Scholar
  24. 24.
    Raza A, Buonamici S, Lisak L, et al. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res. 2004;28:791–803.CrossRefPubMedGoogle Scholar
  25. 25.
    Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597–1602.CrossRefPubMedGoogle Scholar
  26. 26.
    Faderl S, Kantarjian HM. Novel therapies for myelodysplastic syndromes. Cancer. 2004;101:226–241.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2005

Authors and Affiliations

  • Shinji Nakao
    • 1
  • H. Joachim Deeg
    • 2
  • Takayuki Ishikawa
    • 3
  • Judith Marsh
    • 4
  • Alan List
    • 5
  • Masao Tomonaga
    • 6
  1. 1.Cellular Transplantation Biology, Division of Cancer MedicineKanazawa University Graduate School of Medical ScienceKanazawa City IshikawaJapan
  2. 2.Clinical Research DivisionFred Hutchinson Cancer Research CenterSeattleUSA
  3. 3.Department of Hematology/OncologyGraduate School of Medicine, Kyoto UniversityKyotoJapan
  4. 4.Department HaematologySt George’s HospitalLondonUK
  5. 5.Division of Malignant HematologyH. Lee Moffitt Cancer Center and Research Institute, and the University of South FloridaTampaUSA
  6. 6.Department of Hematology, Molecular Medicine UnitAtomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical SciencesNagasakiJapan

Personalised recommendations